Silence Therapeutics plc
SLNCF
$1.80
$0.2012.50%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -89.39% | -70.37% | -99.10% | 1,180.55% | -57.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.39% | -70.37% | -99.10% | 1,180.55% | -57.71% |
| Cost of Revenue | -98.24% | -97.45% | -98.07% | 57.35% | 78.85% |
| Gross Profit | 104.44% | 105.39% | -99.32% | 4,086.30% | -241.98% |
| SG&A Expenses | -24.71% | -26.79% | 15.81% | 30.94% | 22.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.81% | -4.30% | 37.73% | 129.36% | 37.65% |
| Operating Income | 7.25% | 1.88% | -733.77% | 209.44% | -58.67% |
| Income Before Tax | 40.96% | -40.03% | -1,279.59% | 334.35% | -162.96% |
| Income Tax Expenses | -97.96% | -95.61% | -- | -2.40% | 101.61% |
| Earnings from Continuing Operations | 41.04% | -38.47% | -1,134.00% | 159.17% | -240.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.04% | -38.47% | -1,134.00% | 159.17% | -240.28% |
| EBIT | 7.25% | 1.88% | -733.77% | 209.44% | -58.67% |
| EBITDA | 7.31% | 1.88% | -772.26% | 214.46% | -59.29% |
| EPS Basic | 40.00% | -37.00% | -1,048.48% | 148.75% | -167.86% |
| Normalized Basic EPS | 39.93% | -31.87% | -1,184.35% | 293.13% | -107.03% |
| EPS Diluted | 40.00% | -37.00% | -1,048.48% | 148.75% | -167.86% |
| Normalized Diluted EPS | 39.93% | -31.87% | -1,184.35% | 293.13% | -107.03% |
| Average Basic Shares Outstanding | -1.73% | 1.06% | 7.43% | 21.34% | 27.04% |
| Average Diluted Shares Outstanding | -1.73% | 1.06% | 7.43% | 21.34% | 27.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |